Varex Imaging Corporation (Nasdaq: VREX) reported unaudited financial results for Q4 and fiscal year 2025.
Q4FY25 revenues reached $229 million with a 34% non-GAAP gross margin.
FY25 revenues amounted to $845 million with a 35% non-GAAP gross margin.
CEO Sunny Sanyal highlighted the strong performance driven by global CT tube sales and momentum in cargo systems business.
Q4FY25 Revenues
$229 million, up 11% YoY, driven by strong performance in Medical and Industrial segments.
FY25 Revenue Growth
4% YoY increase to $845 million, led by improvements in the Medical segment and strength in the Industrial segment.
Non-GAAP Earnings
Q4FY25 non-GAAP EPS rose to $0.37 from $0.19 in Q4FY24, and non-GAAP EPS for FY25 increased to $0.90.
Key Growth Initiatives
Advancements in innovative technologies like photon counting for CT and successful launch of radiographic detector in India.
- The strong Q4 performance was attributed to global CT tube sales and growth in the cargo systems business.
- FY25 saw revenue growth of 4% YoY, driven by improvements in the Medical segment and continued strength in the Industrial segment.
- Non-GAAP EBITDA increased by 37% to $122 million, with non-GAAP EPS rising by 73% to $0.90 for the year.
- Varex made significant progress in key growth initiatives, including successful product launches and advancements in industrial applications.
Varex Imaging Corporation's strong financial results for Q4 and FY25 demonstrate growth and performance in key segments, driven by strategic initiatives and product innovations.